Rocket Pharmaceuticals Advances Phase 2 Trial for RP-A501 in Danon Disease
Rocket Pharmaceuticals (RCKT) announced progress on its phase 2 trial for RP-A501, a treatment targeting Danon disease. The company confirmed that the path is clear to complete this pivotal study involving 12 male patients. Rocket aims to evaluate co-primary endpoints focused on myocardial LAMP2 protein expression. The update reflects ongoing efforts in developing therapies for rare genetic disorders and signals continued momentum in clinical development. This progress could support future regulatory submissions if trial results meet expectations, potentially enhancing the company's pipeline value.
Tickers: $RCKT
Topics: biotech gene therapy rare diseases